KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) EPS (Weighted Average and Diluted): 2021-2025

Historic EPS (Weighted Average and Diluted) for TherapeuticsMD (TXMD) over the last 5 years, with Sep 2025 value amounting to $0.01.

  • TherapeuticsMD's EPS (Weighted Average and Diluted) rose 120.00% to $0.01 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.01, marking a year-over-year increase of 103.57%. This contributed to the annual value of -$0.20 for FY2024, which is 79.80% up from last year.
  • TherapeuticsMD's EPS (Weighted Average and Diluted) amounted to $0.01 in Q3 2025, which was down 80.00% from $0.05 recorded in Q2 2025.
  • Over the past 5 years, TherapeuticsMD's EPS (Weighted Average and Diluted) peaked at $17.30 during Q4 2022, and registered a low of -$5.70 during Q1 2022.
  • Over the past 3 years, TherapeuticsMD's median EPS (Weighted Average and Diluted) value was -$0.07 (recorded in 2023), while the average stood at -$0.11.
  • In the last 5 years, TherapeuticsMD's EPS (Weighted Average and Diluted) soared by 447.39% in 2022 and then plummeted by 101.87% in 2023.
  • TherapeuticsMD's EPS (Weighted Average and Diluted) (Quarterly) stood at -$4.98 in 2021, then surged by 447.39% to $17.30 in 2022, then slumped by 100.40% to -$0.07 in 2023, then spiked by 114.29% to $0.01 in 2024, then soared by 120.00% to $0.01 in 2025.
  • Its last three reported values are $0.01 in Q3 2025, $0.05 for Q2 2025, and -$0.06 during Q1 2025.